Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer

Xue,Sheng-Liu; Su,Hua-Fang; Hu,Xiao-Qu; Deng,Xia; Hu,Mei-Long; Xie,Cong-Ying

doi:10.3892/ol.2012.914

December 2012 Volume 4 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December 2012 Volume 4 Issue 6

Full Size Image

Article

Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer

Authors:
- Sheng-Liu Xue
- Hua-Fang Su
- Xiao-Qu Hu
- Xia Deng
- Mei-Long Hu
- Cong-Ying Xie
View Affiliations / Copyright

Affiliations: Department of Radiation Oncology and Chemotherapy, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325002, P.R. China, Department of Surgery, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang 325002, P.R. China
Pages: 1309-1314
|
Published online on: September 13, 2012

https://doi.org/10.3892/ol.2012.914
Expand metrics +

Abstract

The optimal adjuvant treatment modality for gastric cancer has not been well defined. The aim of this study was to evaluate the efficacy and feasibility of adjuvant combined systemic and intraperitoneal chemotherapy (ACSIP) in high-risk patients with locally advanced gastric cancer. Between June 2003 and December 2008, 62 eligible patients with serosa-infiltrating and/or node-positive gastric cancer following curative gastrectomy with D2 lymphadenectomy received ACSIP, consisting of intravenous oxaliplatin 85 mg/m2 on day 1 followed by leucovorin (LV) 200 mg/m2 and 5-fluorouracil (5-FU) 450 mg/m2 on days 1-3, intraperitoneal 5-FU 600 mg/m2 on days 4-5 and cisplatin (CDDP) 40 mg/m2 on day 5. Survival rates, the sites of first treatment failure and safety were analyzed. At a median follow-up of 45 months (range 7-101), the 3-year disease-free survival (DFS) and overall survival (OS) rates were 66.1 and 74.2%, respectively. Initial peritoneal and hepatic failures were found in 6 (24.0%) and 3 (12.0%) of the 25 patients with recurrence, respectively. Neutropenia, gastrointestinal side effects and peripheral neuropathy were the most common grade 3-4 toxicities; however, they were all infrequent and manageable. No serious surgical complications or treatment-related mortality was observed. The results of this study indicate that ACSIP is effective and feasible for locally advanced gastric cancer with encouraging survival rates and possibly decreased peritoneal and hepatic recurrences. The benefits of this promising combined adjuvant treatment modality warrant further studies.

View Figures

View References

1.	P ZhaoM DaiW ChenN LiCancer trends in ChinaJpn J Clin Oncol40281285201010.1093/jjco/hyp187
2.	CW WuSS LoKH ShenIncidence and factors associated with recurrence patterns after intended curative surgery for gastric cancerWorld J Surg27153158200312616428
3.	PH SugarbakerW YuY YonemuraGastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancerSemin Surg Oncol21233248200310.1002/ssu.10042
4.	JS MacdonaldSR SmalleyJ BenedettiChemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junctionN Engl J Med345725730200110.1056/NEJMoa010187
5.	D CunninghamWH AllumSP StenningPerioperative chemotherapy versus surgery alone for resectable gastroesophageal cancerN Engl J Med3551120200610.1056/NEJMoa05553116822992
6.	M SasakoS SakuramotoH KataiFive-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancerJ Clin Oncol2943874393201122010012
7.	XJ YangCQ HuangT SuoCytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trialAnn Surg Oncol1815751581201110.1245/s10434-011-1631-5
8.	GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) GroupX PaolettiK ObaBenefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysisJAMA30317291737201010.1001/jama.2010.53420442389
9.	P SunJB XiangZY ChenMeta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancerBr J Surg962633200910.1002/bjs.640819016271
10.	TS LiuY WangSY ChenYH SunAn updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancerEur J Surg Oncol3412081216200810.1016/j.ejso.2008.02.00218353606
11.	DZ XuYQ ZhanXW SunSM CaoQR GengMeta-analysis of intraperitoneal chemotherapy for gastric cancerWorld J Gastroenterol1027272730200415309728
12.	TD YanD BlackPH SugarbakerJ ZhuY YonemuraG PetrouDL MorrisA systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancerAnn Surg Oncol1427022713200710.1245/s10434-007-9487-4
13.	PH SugarbakerAdjuvant intraperitoneal chemotherapy for advanced primary gastric cancerScand J Surg95270273200617249276
14.	DK ArmstrongB BundyL WenzelIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med3543443200610.1056/NEJMoa05298516394300
15.	American Joint Committe on Cancer (AJCC)Cancer staging handbook: TNM classification of malignant tumours6th editionSpringerNew York991062002
16.	T SanoT AikoNew Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised pointsGastric Cancer1497100201110.1007/s10120-011-0040-621573921
17.	G MatharuO TuckerD AldersonSystematic review of intraperitoneal chemotherapy for gastric cancerBr J Surg9812251235201110.1002/bjs.758621644239
18.	W ScheithauerGV KornekA MarczellCombined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinomaBr J Cancer77134913541998
19.	OT AtiqDP KelsenMH ShiuPhase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancerJ Clin Oncol114254331993
20.	Y ZuoM XuD ShenWD LuJF LuPostoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patientsZhonghua Zhong Liu Za Zhi262472492004
21.	C ShiB YangQ ChenJ YangN FanRetrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancerOncology80289295201110.1159/000329075
22.	M D’AngelicaM GonenMF BrennanAD TurnbullM BainsMS KarpehPatterns of initial recurrence in completely resected gastric adenocarcinomaAnn Surg240808816200415492562
23.	RL SchilskyKE ChoiJ GrayhackD GrimmerC GuarnieriL FullemPhase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancerJ Clin Oncol8205420611990
24.	W YuI WhangA AverbachD ChangPH SugarbakerMorbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancerAm Surg641104110819989798779
25.	HR RosenG JatzkoS RepseAdjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical OncologyJ Clin Oncol16273327381998
26.	F De VitaL VecchioneG GaliziaPerspectives in adjuvant therapy of gastric cancerOncology773842200920130430
27.	A BittoniE MaccaroniM ScartozziR BerardiS CascinuChemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectivesEur Rev Med Pharmacol Sci14309314201020496540

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles